|
參考文獻
Catto, A., Carter, A., & Ireland, H. (1995). Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arteriosclerosis Thrombosis and Vascular Biology. 15,783-785.
Frick, P.G., Riedler, G., & Brogli, H. (1967). Dose response and minimal daily requirement for Vitamin K in man. Journal Applied Physiology. 23(3),387-389.
Loeliger, E.A. (1985). Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thrombosis and Haemostasis. 53, 148-54.
Loscalzo, J., & Schafer, A.I. (1998). Thrombosis and hemorrhage (2nd ed.). Philadelphia: Lippincott Williams & Wilkins.
Larsen, F.G., Larsen, C.G., Andersen, S., Norgaard, A., Hansen, H.E., & Brodersen, R. (1986). Warfarin binding to plasma albumin, measured in patients and related to fatty acid concentration. European Journal Clinical Investigation. 16,22-7. O’Reilly, R.A., & Aggeler, P.M. (1968). Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy without a loading dose. Circulation. 38,169-77.
Porter, R.S., & Sawyer, W.T. (1992). Applied Pharmacokinetics Vanconver: Applied therapeutics.
Rothschild, B.M.,& Helbling, M.E. (2001). Two sides of the warfarin issue:diligence versus potency. American Journal Medicine. 110,272-274.
Shibata, Y., Hashimoto, H., Kurata, C., Ohno, R., Kazui, T., & Takinami, M. (1998). Influence of physical activity on warfarin therapy. Thrombosis and Haemostasis. 80 ,203-4.
Takahashi, H., & Echizen, H. (2001). Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics 40(8), 587-603.
Wannamethee, S.G., Lowe, G.D., Whincup, P.H., Rumley, A., Walker, M., & Lennon, L. (2002). Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 105(15), 1785-1790.
|